Eisai drug extends survival in patients with rare cancers
A drug made by Japan’s Eisai Co that was originally derived from sea sponges helped extend lives of patients with soft-tissue cancers known as sarcomas by two months, a significant advance for these rare cancers with few treatment options, Belgian researchers said on Saturday. The researchers studied the drug, known as eribulin, in 452 patients with two forms of sarcomas – leiomyosarcoma, which starts in smooth muscles, and adipocytic sarcoma,